Explain Hepatitis B from Park's Textbook of Preventive and Social Medicine

Reading File

Finding Sources

Reading File

I now have comprehensive content from Park's Textbook. Let me compile a thorough, well-structured answer.

Hepatitis B - Park's Textbook of Preventive and Social Medicine

Definition

Hepatitis B (formerly "serum" hepatitis) is an acute systemic infection with major pathology in the liver, caused by the hepatitis B virus (HBV). HBV infection can be acute or chronic, ranging from asymptomatic infection to severe or, rarely, fulminant hepatitis. Acute hepatitis B is usually self-limiting with hepatocellular necrosis and a case fatality rate of 0.5-1%. Chronic hepatitis B (CHB) is defined as persistent HBV infection with or without active viral replication, and evidence of hepatocellular injury and inflammation.

Problem Statement

Global Burden

HBV infection is endemic worldwide, especially in tropical and developing countries.
HBsAg prevalence classifies endemicity: ≥8% = highly endemic, 5-7% = high intermediate, 2-4% = low intermediate, <2% = low endemic.
In 2015, global prevalence was estimated at 3.5%, with approximately 257 million persons living with chronic HBV infection.
The highest regional prevalence is in the African (6.1%) and Western Pacific (6.2%) WHO Regions.
In 2015, an estimated 887,220 deaths resulted from HBV - 337,454 from hepatocellular carcinoma (HCC), 462,690 from cirrhosis, and 87,076 from acute hepatitis.

India

India is in the "intermediate" endemicity zone for HBV.
HBsAg prevalence among blood donors ranges from 1.1-5.6% across different regions.
Perinatal transmission is a major source of CHB, and this becomes a significant public health problem when infected children grow into adults.

Co-infections

~2.7 million of the 36.7 million HIV-infected people worldwide are co-infected with HBV.
~10-15% of patients with CHB are co-infected with HCV.
HDV (Hepatitis Delta Virus) infection occurs exclusively in HBV-infected individuals, as HDV is a deficient virus requiring HBV surface proteins to form its envelope.

Epidemiological Determinants

Agent Factors

(a) Agent: HBV was discovered by Blumberg in 1963. It is a complex, 42 nm, double-shelled DNA virus, originally known as the "Dane particle". The virus replicates in liver cells. In the serum of infected patients, HBV occurs in three morphological forms:

Small spherical particles (~22 nm diameter) - antigenic, stimulate surface antibodies; non-infectious
Tubules of varying length and diameter - non-infectious
Dane particle - the complete virion, the only infectious form

(b) Reservoir of Infection: Man is the only reservoir. The infection can spread from carriers or from cases. Persistent carrier state = HBsAg positive (with or without HBeAg) for more than 6 months.

(c) Infective Material: Contaminated blood is the main source. The virus is also found in saliva, vaginal secretions, and semen of infected persons.

(d) Resistance: The virus is quite stable and can survive for at least 7 days on environmental surfaces. It is destroyed by sodium hypochlorite and by heat sterilization in an autoclave for 30-60 minutes.

(e) Period of Communicability: The virus is present in blood during the incubation period (a month before jaundice) and the acute phase. Communicability lasts usually several months (occasionally years in chronic carriers) - until HBsAg disappears and surface antibody appears.

Host Factors

(a) Age: HBV infection outcomes are strongly age-dependent:

Age at Infection	Risk of Acute Hepatitis	Risk of Chronicity
Perinatal	~1%	80-90%
Early childhood (1-5 years)	~10%	30-50%
Late (>5 years) / Adults	~30%	<5%

Mortality from fulminant hepatitis B is approximately 70%.

(b) High-Risk Groups:

Healthcare workers, dialysis patients
Recipients of blood or blood products
Intravenous drug users
Sexually promiscuous persons, male homosexuals
Prisoners
Close household contacts of carriers
Newborns of HBsAg-positive mothers
Persons of transgender

(c) Immunity: Infection confers long-lasting immunity. Anti-HBs antibody is the marker of immunity.

Environmental Factors (Routes of Transmission)

(a) Parenteral Route: The primary mode of transmission. HBV spreads via:

Blood transfusions with infected blood
Contaminated syringes and needles (IV drug users, tattooing, acupuncture)
Dialysis equipment
Accidental needle-stick injuries in health workers

(b) Perinatal Transmission: An important factor for high HBV prevalence in China and SE Asia. Most infections occur at birth (not in utero) through maternal blood leaking into the baby's circulation. Unless vaccinated at birth, the majority of babies born to HBeAg-positive mothers become chronically infected. The infection in babies is usually anicteric and HBsAg appears 60-120 days after birth.

(c) Sexual Transmission: HBV spreads via intimate contact. Body fluids including saliva, vaginal, menstrual, and seminal fluids are implicated. Sexually promiscuous persons, particularly male homosexuals, are at very high risk.

(d) Horizontal Transmission (Child-to-Child): Responsible for a majority of HBV infections in parts of the world other than Asia. Spread occurs through physical contact between children with skin cuts or grazes, sharing the same bed, or playing together.

Incubation Period

30 to 180 days (average approximately 75 days). Lower doses of virus often result in a longer incubation period.

Clinical Picture

The symptoms of hepatitis B are similar to other viral hepatitis. The picture is complicated by the carrier state and by chronic liver disease that may follow infection.

Natural history of chronic HBV:

Some patients: inactive CHB, no significant liver disease
Others: progressive liver fibrosis → cirrhosis → end-stage liver disease → HCC
Longitudinal studies show an 8-20% cumulative risk of developing cirrhosis over 5 years in untreated CHB
In those with cirrhosis: ~20% annual risk of hepatic decompensation; annual HCC incidence 1-5%
Untreated decompensated cirrhosis: only 15-40% survival at 5 years

Cofactors that accelerate disease progression: co-infection with HIV, HCV, HDV; alcohol use.

Diagnosis

There are three distinct antigen-antibody systems relating to HBV infection. Common serological markers:

Marker	Significance
HBsAg (surface antigen)	First marker to appear; indicates active infection; positive = carrier if persistent >6 months
Anti-HBs	Marker of immunity/recovery; appears after HBsAg clears
Anti-HBc (IgM)	Indicates recent/acute infection
Anti-HBc (IgG)	Indicates past or chronic infection
HBeAg	Marker of active viral replication and high infectivity
Anti-HBe	Appears after HBeAg clearance; indicates reduced infectivity
HBV DNA	Direct measure of viral load; used to monitor treatment

Detection methods include rapid diagnostic tests (RDTs) and laboratory-based immunoassays - enzyme immunoassays (EIAs), chemiluminescence immunoassays (CLIAs), and electrochemiluminescence immunoassays (ECLs), typically in serum/plasma or oral fluid/capillary blood.

Prevention and Containment

Since there is no specific treatment for acute hepatitis B, prevention is the major aim.

a. Hepatitis B Vaccine

The recombinant hepatitis B vaccine was introduced in 1986 and has replaced the plasma-derived vaccine. Its active substance is HBsAg.

Dosing:

Adults: 10-20 micrograms at 0, 1, and 6 months
Children under 10 years: half the adult dose at same intervals
Route: Intramuscular injection; deltoid muscle preferred in adults, anterolateral thigh in infants/children <2 years
Intradermal route is not recommended (less reliable immune response, especially in children)

Schedules in India (National Immunization Programme):

4-dose schedule: Birth dose + 3 doses at 6, 10, and 14 weeks along with DPT (pentavalent vaccine: DPT + HepB + Hib)

Key points:

HepB vaccine does not interfere with other vaccines and can be given with BCG (at different sites)
In high endemicity areas (HBsAg prevalence >8%), the birth dose should be given within 24 hours of birth
Global coverage with 3 doses of HepB vaccine reached 84% in 2015
By 2015, 185 countries had incorporated HepB vaccination in national infant schedules

b. Hepatitis B Immunoglobulin (HBIG)

HBIG provides passive immunity. It is given for post-exposure prophylaxis (PEP).

HBIG dose: 0.05-0.07 ml/kg, given as soon as possible, ideally within 24 hours of exposure
Combined with HBV vaccine (1.0 ml / 20 mcg IM) within 7 days of exposure, followed by 2nd and 3rd doses at 1 and 6 months

HBIG + Vaccine is ideal for:

Persons accidentally exposed to HBsAg-positive blood (needle-stick injuries)
Prevention of perinatal transmission - newborns of carrier mothers

c. Blood Donor Screening

All blood donors must be screened for HBsAg (Australia antigen) and positive donors rejected
Voluntary blood donation is preferred (purchased blood has higher risk of post-transfusion hepatitis)
Adequate sterilization of all instruments must be ensured

d. Other Measures

Carriers must not share razors or toothbrushes, should use barrier methods of contraception, and must not donate blood
High-risk groups to be screened for HBsAg: household/sexual contacts of CHB patients, HIV-infected persons, PWID (people who inject drugs), men who have sex with men, sex workers, prisoners, transgender persons

Treatment

There is no specific treatment for acute hepatitis B. Care is aimed at:

Maintaining comfort and adequate nutritional balance
Replacement of fluids lost from vomiting and diarrhoea

Chronic Hepatitis B

CHB is defined as persistence of HBsAg for 6 months or more after acute HBV infection. The WHO "5Cs" framework for hepatitis testing applies:

Consent - voluntary and informed
Confidentiality
Correct test results
Counselling
Connection - linkage to prevention, treatment, and care services

Early identification enables infected persons to receive care and treatment to prevent or delay onset of liver disease, and to prevent transmission through vaccination of non-immune household contacts and sex partners.

Source: Park's Textbook of Preventive and Social Medicine, Chapter on Viral Hepatitis.

This is a shared conversation. Sign in to Orris to start your own chat.